Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERA-923 in Metastatic Breast Cancer Refractory to Tamoxifen
NCT00006369Phase 2Unknown
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pipendoxifene in breast cancer (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Efficacy of ERA-923 at 48 weeks. Status: unknown.
02
Drugs
pipendoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006369.